Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

ClinicalTrials.gov ID: NCT03434119

Public ClinicalTrials.gov record NCT03434119. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua™100/33 Versus Lantus® in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Primary Objective: * To demonstrate the superiority of Soliqua 100/33 versus Lantus in the hemoglobin A1c (HbA1c) change within the overall population. * To demonstrate the benefit of Soliqua 100/33 versus Lantus in the HbA1c within each ethnic/racial subgroup evaluated (ie, Hispanics of any race, non-Hispanic black/African Americans and non-Hispanic Asians). Secondary Objective: * To assess the effects of Soliqua 100/33 versus Lantus on the secondary efficacy parameters within each ethnic/racial subgroup evaluated. * To assess the change in daily insulin glargine dose within each ethnic/racial subgroup. * To evaluate the safety and tolerability (e.g., gastrointestinal tolerability) of Soliqua 100/33 versus Lantus within each ethnic/racial subgroup.

Study identification

NCT ID
NCT03434119
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sanofi
Industry
Enrollment
241 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 19, 2018
Primary completion
Jan 6, 2019
Completion
Jan 6, 2019
Last update posted
Mar 27, 2022

2018 – 2019

United States locations

U.S. sites
85
U.S. states
19
U.S. cities
66
Facility City State ZIP Site status
Investigational Site Number 8400072 Montgomery Alabama 36106
Investigational Site Number 8400077 Little Rock Arkansas 72204
Investigational Site Number 8400095 Little Rock Arkansas 72205
Investigational Site Number 8400013 Little Rock Arkansas 72211
Investigational Site Number 8400076 Anaheim California 92801-4123
Investigational Site Number 8400052 Anaheim California 92801
Investigational Site Number 8400069 Anaheim California 92805
Investigational Site Number 8400060 Burbank California 91505
Investigational Site Number 8400049 Cerritos California 90703
Investigational Site Number 8400078 Chula Vista California 91910
Investigational Site Number 8400047 Escondido California 92025
Investigational Site Number 8400066 Fountain Valley California 92708
Investigational Site Number 8400050 Greenbrae California 94904
Investigational Site Number 8400092 Huntington Park California 90255
Investigational Site Number 8400015 Los Angeles California 90017
Investigational Site Number 8400011 Los Angeles California 90057
Investigational Site Number 8400301 Los Angeles California 90094
Investigational Site Number 8400302 Los Angeles California 90094
Investigational Site Number 8400303 Los Angeles California 90094
Investigational Site Number 8400304 Los Angeles California 90094
Investigational Site Number 8400006 Los Gatos California 95032
Investigational Site Number 8400048 Oakland California 94612
Investigational Site Number 8400053 Orange California 92868
Investigational Site Number 8400084 Pomona California 91766
Investigational Site Number 8400081 Pomona California 91767
Investigational Site Number 8400042 Rancho Cucamonga California 91730
Investigational Site Number 8400063 San Carlos California 94070
Investigational Site Number 8400091 San Diego California 92114
Investigational Site Number 8400086 San Jose California 95148
Investigational Site Number 8400074 Santa Ana California 92701
Investigational Site Number 8400037 Temecula California 92591
Investigational Site Number 8400087 Vallejo California 94592
Investigational Site Number 8400024 Van Nuys California 91405
Investigational Site Number 8400007 Ventura California 93003
Investigational Site Number 8400054 Englewood Colorado 80113
Investigational Site Number 8400023 Hamden Connecticut 06517
Investigational Site Number 8400041 Gainesville Florida 32653
Investigational Site Number 8400075 Jacksonville Florida 32204
Investigational Site Number 8400036 Miami Florida 33144
Investigational Site Number 8400017 Miami Florida 33176
Investigational Site Number 8400016 Miami Lakes Florida 33014
Investigational Site Number 8400014 Ocoee Florida 34761
Investigational Site Number 8400028 Port Charlotte Florida 33952
Investigational Site Number 8400097 St. Petersburg Florida 00000
Investigational Site Number 8400035 St. Petersburg Florida 33713
Investigational Site Number 8400094 Tampa Florida 33634
Investigational Site Number 8400025 Atlanta Georgia 30303
Investigational Site Number 8400051 Atlanta Georgia 30310
Investigational Site Number 8400093 Atlanta Georgia 30318
Investigational Site Number 8400005 Savannah Georgia 31406-2675
Investigational Site Number 8400038 Chicago Illinois 60607
Investigational Site Number 8400088 Chicago Illinois 60607
Investigational Site Number 8400031 Des Plaines Illinois 60018
Investigational Site Number 8400064 Evanston Illinois 60201
Investigational Site Number 8400057 Gurnee Illinois 60031
Investigational Site Number 8400030 Gretna Louisiana 70053
Investigational Site Number 8400009 New Orleans Louisiana 70124
Investigational Site Number 8400065 Baltimore Maryland 21237
Investigational Site Number 8400061 Rockville Maryland 20852
Investigational Site Number 8400079 Chelsea Michigan 48118
Investigational Site Number 8400001 Flint Michigan 48504
Investigational Site Number 8400012 Flint Michigan 48532-3447
Investigational Site Number 8400090 Las Vegas Nevada 89117
Investigational Site Number 8400082 Las Vegas Nevada 89148
Investigational Site Number 8400018 Linden New Jersey 07036
Investigational Site Number 8400003 The Bronx New York 10455
Investigational Site Number 8400062 Philadelphia Pennsylvania 19107
Investigational Site Number 8400043 Columbia South Carolina 29204
Investigational Site Number 8400021 Dallas Texas 75230
Investigational Site Number 8400040 Fort Worth Texas 76132
Investigational Site Number 8400045 Houston Texas 77089
Investigational Site Number 8400002 Humble Texas 77338
Investigational Site Number 8400039 Kerrville Texas 78028
Investigational Site Number 8400096 Lufkin Texas 75904
Investigational Site Number 8400027 San Antonio Texas 78228
Investigational Site Number 8400083 San Antonio Texas 78230
Investigational Site Number 8400008 Splendora Texas 77372
Investigational Site Number 8400055 Spring Texas 77379
Investigational Site Number 8400070 Sugar Land Texas 77478
Investigational Site Number 8400085 Sugar Land Texas 77479
Investigational Site Number 8400059 Webster Texas 77598
Investigational Site Number 8400044 Manassas Virginia 20110
Investigational Site Number 8400068 Norfolk Virginia 23510
Investigational Site Number 8400033 Richmond Virginia 23219
Investigational Site Number 8400029 Richland Washington 99352

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03434119, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 27, 2022 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03434119 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →